Hemp being federally legal would be huge for the CBD industry, as CBD oil made from hemp extract (a plant that has very low amounts of THC) would be legal. A new, more available form of CBD would also allow for more research on the subject of cannabidiol, and perhaps the entire marijuana plant. More research brings the potential of coming closer to full legalization.
As with a fermented food like kombucha, slight natural variations are normal and to be expected in a product such as CBD oil because it is made from living plants. Changes in the weather, soil, and water can all impact the biology of the source material. While we verify Certificates of Analysis (and take many other criteria into consideration during our review process), even the most reputable five-star companies have no way to control for every variable in this organic process.
Figure 2. Receptor Systems Involved in CBD’s Potential Therapeutic Applications. CBD interacts, either directly or indirectly, with many different receptor systems in the brain. It indirectly influences the major cannabinoid receptor in the brain by decreasing THC’s ability to stimulate this receptor. It also interacts with a variety of other receptors. A subset of these are shown here. Each red shape represents a different brain receptor that might be found on a neuron. Some of the potential therapeutic applications associated with CBD’s interaction with each receptor system are listed below each receptor.
Great public concern attends recreational cannabis usage and risks of dependency. The addictive potential of a drug is assessed on the basis of five elements: intoxication, reinforcement, tolerance, withdrawal and dependency. Drug abuse liability (DAL) is also assessed by examining a drug's rates of abuse and diversion. US Congress placed cannabis in Schedule I of the Controlled Substances Act in 1970, with drugs categorized as addictive, dangerous, possessing severe abuse potential and no recognized medical value. Marinol was placed in Schedule II, the category for drugs with high abuse potential and liability to produce dependency, but certain recognized medical uses, after its FDA approval in 1985. Marinol was reassigned to Schedule III in 1999, a category denoting a lesser potential for abuse or lower dependency risk after documentation that little abuse or diversion (Calhoun et al 1998) had occurred. Nabilone was placed and has remained in Schedule II since 1985.
Hempseed is considered by leading researchers and medical doctors to be one of the most nutritious food sources on the planet. Shelled hempseed is packed with 33% pure digestible protein and is rich in iron and vitamin E as well as omega-3 and GLA. A recent report funded by the Canadian government states that hemp protein comprises 66% high-quality edistin protein, and that hempseed contains the highest percentage of this of any plant source. Unlike soy, hemp is not genetically modified, and it doesn't contain the anti-nutritional qualities commonly found in soy.
A major problem with cannabis is its short half life. It only lasts two hours. Repeated dosing of a chemical – that is what it is, natural or not, that makes you high is just not realistic if you want a life. It also has a horrid withdrawal syndrome if you are a regular user and then travel and can’t use for legal reasons. I almost ended up in Hospital it was VILE. And there are drug interactions. It makes me itch. What exactly it is reacting with from what I, prescribed I’m now sure. No since having an epidural it affects me like speed in a horrid way. I haven’t slept since 0230 and it’s now 2040, two night in the last week I didn’t sleep at all and I’ve been horribly manic.
A recent study published in The International Journal of Neurophamacologypoints to cannabidiol (CBD) as a cause of neurogenesis in the brain; specifically in the Hippocampus, an area typically associated with conscious memory and navigation. However, the researchers believe that CBD’s anxiety relief may be due to this neurogenesis in the brain. You can read our full article on the study here.
The glutamatergic system is integral to development and maintenance of neuropathic pain, and is responsible for generating secondary and tertiary hyperalgesia in migraine and fibromyalgia via NMDA mechanisms (Nicolodi et al 1998). Thus, it is important to note that cannabinoids presynaptically inhibit glutamate release (Shen et al 1996), THC produces 30%–40% reduction in NMDA responses, and THC is a neuroprotective antioxidant (Hampson et al 1998). Additionally, cannabinoids reduce hyperalgesia via inhibition of calcitonin gene-related peptide (Richardson et al 1998a). As for Substance P mechanisms, cannabinoids block capsaicin-induced hyperalgesia (Li et al 1999), and THC will do so at sub-psychoactive doses in experimental animals (Ko and Woods 1999). Among the noteworthy interactions with opiates and the endorphin/enkephalin system, THC has been shown to stimulate beta-endorphin production (Manzanares et al 1998), may allow opiate sparing in clinical application (Cichewicz et al 1999), prevents development of tolerance to and withdrawal from opiates (Cichewicz and Welch 2003), and rekindles opiate analgesia after a prior dosage has worn off (Cichewicz and McCarthy 2003). These are all promising attributes for an adjunctive agent in treatment of clinical chronic pain states.
Why support the endocannabinoid system? The endocannabinoid system (ECS) is gaining attention in the public eye for its role in contributing to an individual’s overall health and well-being by supporting the body’s physiological homeostasis. The ECS regulates nearly every metabolic process in the body system. A well-balanced ECS encourages favorable conditions in the body system, impacting the body’s ability to manage metabolic stress1 and may support overall health and well-being.2